Resilience and the Department of Therapeutic Innovation and Early Stage Trials are leveraging remote patient monitoring for clinical research in oncology

The first early stage center to implement remote patient monitoring 

Currently serving over 14,000 patients across 110 healthcare facilities in France and Belgium, Resilience’s mission is to redefine and personalize cancer care. Co-founded with Gustave Roussy, the leading cancer center in Europe and the 4th worldwide, the company has placed data at the core, believing that its comprehensive analysis can provide a deeper understanding of each patient’s needs. This enables the creation of tailored care pathways, delivering the right treatment at the right time. 

Further strengthening its commitment to advancing oncology clinical research, Resilience has deployed its remote patient monitoring platform at the Department of Therapeutic Innovation and Early Stage Trials, one of the largest early-phase centers in Europe at the end of 2024. With a team of over 140 professionals, including 16 physicians, the DITEP enrolls annually between 400 and 500 patients in clinical trials. It stands out for its expertise in evaluating innovative treatments, particularly in Phase I and I-II clinical studies. These trials’ primary objective is to assess the safety, pharmacokinetics, and efficacy of new molecules in humans. The DITEP has screened 2,700 patients and enrolled around 450 patients per year in Phase I and I-II trials. With more than 139 protocols underway, the department develops new therapeutic strategies and combinations for patients with all types of advanced cancers, including solid tumors and hematological cancers. In October 2024, Resilience was implemented within the DITEP, making it the first early stage center to integrate Resilience remote patient monitoring. 

Remote patient monitoring, a valuable resource enhancing patient care and clinical research 

The early-phase trials conducted at the DITEP allow the administration of innovative molecules to patients for the first time. Continuous follow-up is crucial for assessing toxicities and immediately and proactively notify the medical teams of any adverse events, ensuring they are reported to the trial sponsor. The goal of deploying Resilience’s solution within DITEP is to better define, characterize, and monitor the side effects of patients receiving these new treatments. 

Through real-time data collection, remote patient monitoring allows the systematic and early identification of any new symptoms or adverse effects related to these novel therapies, which may sometimes be less recognized by clinicians, as well as subtle signals that could not previously be detected. This enables a better anticipation and a more detailed analysis of side effects for improved management. Thanks to alerts processed by coordinating nurses, the implementation of remote patient monitoring also represents a significant time-saving benefit for the medical teams. 

Finally, Resilience’s deployment within the DITEP addresses a critical long-term challenge for clinical research in oncology. The data collected through remote patient monitoring usage is a valuable resource for research. A comprehensive analysis supports defining the best recommended dose prescribed to the patient for use in Phase II and III trials. This aims to offer the most relevant dose and avoid some development failures in Phase III due to an improper dose definition. 

To date, more than 110 patients are actively being remotely monitored with Resilience. The long-term objective is to systematically include every new patient at the DITEP in Resilience care pathway. 

Pr Christophe Massard, Head of DITEP, et Dr Kaissa Ouali, Medical oncologist and Specialist in Cancer Center, DITEP: "This advancement transforms patient monitoring by enabling regular, precise remote patient monitoring, while improving their well-being and the quality of care. Through real-time data collection, we accelerate the development of innovative treatments. Each data collected represents a significant step forward in the fight against cancer. This partnership exemplifies the future of medical care, where technology and humanity come together to provide personalized, optimized healthcare solutions." 

Dr Charles Ferté, Chief Medical & Patient Experience Officer of Resilience, added: "With the deployment of remote patient monitoring, for the first time within an Early Phase Trials Department, we are further strengthening our position as a major contributor to clinical research in oncology. The data collected through remote patient monitoring and its comprehensive analysis represent a considerable resource for improving and personalizing patient care and, in the long term, accelerating therapeutic innovation." 
*The Drug-Dosing Conundrum in Oncology — When Less Is More. Shah et al. NEJM 2021

Background on Resilience
Resilience offers a comprehensive Remote Patient Care solution dedicated to cancer patients and healthcare professionals. Combining a mobile application with Remote Patient Monitoring platform, Resilience ensures better care by personalizing, humanizing, and improving the care pathway. The mobile application supports individuals affected by cancer in managing treatment-related side effects and fostering self-care. Meanwhile, the Remote Patient Monitoring platform, a IIa class medical device, enables healthcare professionals to better understand and improve patient care. In October of 2023, following a positive opinion from the Haute Autorité de Santé (HAS), Resilience PRO became the first medical device in oncology to receive a full approval in France (i.e. registered as a brand name on the List of Medical Remote Monitoring Activities (LATM), thus allowing its reimbursement by the French National Insurance system. Co-founded with Gustave Roussy, the leading cancer center in Europe. The company partners with more than 110 centers and supports over 14,000 patients. www.resilience.care 

Background on Gustave Roussy
Ranked as the leading French and European Cancer Centre and fourth in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors, and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: 40% of patients treated are included in clinical studies. For further information: www.gustaveroussy.fr - X, Facebook, LinkedIn, Instagram 

Press Contact
Sibylle Pichot, Head of Communication & Brand Resilience, sibylle.pichot@resilience.care
Claire Parisel, Responsable Relations Médias Gustave Roussy, CLAIRE.PARISEL@gustaveroussy.fr